Literature DB >> 27579165

Skeletal implications and management of cystinosis: three case reports and literature review.

Justine Bacchetta1, Marcella Greco2, Aurélia Bertholet-Thomas3, François Nobili4, Jozef Zustin5, Pierre Cochat6, Francesco Emma2, Georges Boivin7.   

Abstract

Hypophosphatemic rickets and short stature are observed in nephropathic cystinosis, an orphan autosomal recessive lysosomal storage disease due to a deficiency of cystinosin (CTNS gene). Although bone impairment is not common, it nevertheless appears to be more and more discussed by experts, even though the exact underlying pathophysiology is unclear. Four hypotheses are currently discussed to explain such impairment: copper deficiency, bone consequences of severe hypophosphatemic rickets during infancy, cysteamine toxicity and abnormal thyroid metabolism. In murine models, the invalidation of the CTNS gene is associated neither with renal phosphate wasting nor with renal failure, but causes severe osteopenia and growth retardation, thus raising the hypothesis of a specific underlying bone defect in cystinosis. Moreover, the in vitro ability of mesenchymal stromal cells isolated from bone marrow to differentiate along the osteoblastic lineage is reduced in patients with cystinosis as compared with cells obtained from healthy controls, this cellular abnormality being reverted after cysteamine treatment. From our experience of three pediatric patients with cystinosis and severe bone deformations having undergone a thorough biochemical evaluation, as well as a bone biopsy, we conclude that even though copper deficiency, high-doses cysteamine regimens and abnormal thyroid metabolism may worsen the bone picture in cystinosis patients, the exact pathophysiology of such impairment remains to be defined. The role of chronic hypoparathyroidism due to chronic phosphate wasting could also be discussed. In the future, larger and prospective studies should focus on this topic because of the potential major impact on patients' quality of life.

Entities:  

Year:  2016        PMID: 27579165      PMCID: PMC4988218          DOI: 10.1038/bonekey.2016.55

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  15 in total

1.  Nephropathic cystinosis--a gap between developing and developed nations.

Authors:  Aurelia Bertholet-Thomas; Justine Bacchetta; Velibor Tasic; Pierre Cochat
Journal:  N Engl J Med       Date:  2014-04-03       Impact factor: 91.245

2.  Dissecting aneurysm of aorta in rats fed with cysteamine.

Authors:  A P Jayaraj
Journal:  Br J Exp Pathol       Date:  1983-10

3.  Progressive destructive bone changes in patients with cystinosis.

Authors:  Maria Klusmann; William Van't Hoff; Fergal Monsell; Amaka C Offiah
Journal:  Skeletal Radiol       Date:  2013-09-28       Impact factor: 2.199

4.  A co-occurrence of osteogenesis imperfecta type VI and cystinosis.

Authors:  Tracy Tucker; Tanya Nelson; Sandra Sirrs; Peter Roughley; Francis H Glorieux; Pierre Moffatt; Kamilla Schlade-Bartusiak; Lindsay Brown; Frank Rauch
Journal:  Am J Med Genet A       Date:  2012-04-23       Impact factor: 2.802

5.  Cysteamine toxicity in patients with cystinosis.

Authors:  Martine T P Besouw; Richard Bowker; Jean-Paul Dutertre; Francesco Emma; William A Gahl; Marcella Greco; Marc R Lilien; John McKiernan; François Nobili; Jerry A Schneider; Flemming Skovby; Lambertus P van den Heuvel; William G Van't Hoff; Elena N Levtchenko
Journal:  J Pediatr       Date:  2011-07-23       Impact factor: 4.406

6.  Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine.

Authors:  M Broyer; M J Tête; G Guest; J P Berthélémé; F Labrousse; M Poisson
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

7.  Improved renal function in children with cystinosis treated with cysteamine.

Authors:  T C Markello; I M Bernardini; W A Gahl
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

8.  Nephropathic cystinosis: an international consensus document.

Authors:  Francesco Emma; Galina Nesterova; Craig Langman; Antoine Labbé; Stephanie Cherqui; Paul Goodyer; Mirian C Janssen; Marcella Greco; Rezan Topaloglu; Ewa Elenberg; Ranjan Dohil; Doris Trauner; Corinne Antignac; Pierre Cochat; Frederick Kaskel; Aude Servais; Elke Wühl; Patrick Niaudet; William Van't Hoff; William Gahl; Elena Levtchenko
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

9.  Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patient.

Authors:  Antonella Conforti; Anna Taranta; Simone Biagini; Nadia Starc; Angela Pitisci; Francesco Bellomo; Valentina Cirillo; Franco Locatelli; Maria Ester Bernardo; Francesco Emma
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

10.  Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.

Authors:  Rui Hu; Zhisheng Wang; Quanhui Peng; Huawei Zou; Hongze Wang; Xiaoqiang Yu; Xiaoping Jing; Yixin Wang; Binghai Cao; Shanke Bao; Wenhua Zhang; Suonan Zhao; Hanzhong Ji; Xiangying Kong; Quanxi Niu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

View more
  8 in total

Review 1.  Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update.

Authors:  Binata Marik; Arvind Bagga; Aditi Sinha; Pankaj Hari; Arundhati Sharma
Journal:  J Pediatr Genet       Date:  2018-01-28

2.  Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment.

Authors:  Aurélia Bertholet-Thomas; Debora Claramunt-Taberner; Ségolène Gaillard; Georges Deschênes; Elisabeth Sornay-Rendu; Pawel Szulc; Martine Cohen-Solal; Solenne Pelletier; Marie-Christine Carlier; Pierre Cochat; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2018-02-12       Impact factor: 3.714

Review 3.  The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.

Authors:  Stephanie Cherqui; Pierre J Courtoy
Journal:  Nat Rev Nephrol       Date:  2016-12-19       Impact factor: 28.314

Review 4.  Peripheral Blood Mononuclear Cells (PBMCs) to Dissect the Underlying Mechanisms of Bone Disease in Chronic Kidney Disease and Rare Renal Diseases.

Authors:  Irma Machuca-Gayet; Justine Bacchetta; Julie Bernardor; Candide Alioli; Marie-Noelle Meaux; Olivier Peyruchaud
Journal:  Curr Osteoporos Rep       Date:  2021-11-13       Impact factor: 5.096

Review 5.  Bone Disease in Nephropathic Cystinosis: Beyond Renal Osteodystrophy.

Authors:  Irma Machuca-Gayet; Thomas Quinaux; Aurélia Bertholet-Thomas; Ségolène Gaillard; Débora Claramunt-Taberner; Cécile Acquaviva-Bourdain; Justine Bacchetta
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 6.  Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts.

Authors:  Dieter Haffner; Maren Leifheit-Nestler; Candide Alioli; Justine Bacchetta
Journal:  Cells       Date:  2022-01-05       Impact factor: 6.600

7.  Cysteamine affects skeletal development and impairs motor behavior in zebrafish.

Authors:  Chao Chen; Yongliang Zheng; Xue Li; Li Zhang; Kangyu Liu; Sujie Sun; Zilin Zhong; Hongmei Hu; Fasheng Liu; Guanghua Xiong; Xinjun Liao; Huiqiang Lu; Yanlong Bi; Jianjun Chen; Zigang Cao
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

Review 8.  Hematopoietic Stem Cell Gene Therapy for Cystinosis: From Bench-to-Bedside.

Authors:  Stephanie Cherqui
Journal:  Cells       Date:  2021-11-23       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.